Pitched 31st January 2022

Real-world analysis of the use of interim18F-FDG-PET/CT in Diffuse Large B-cell Lymphoma as a prognostic and decision-making tool.

This study aims to examine the use of interim PET in DLBCL, the clinical decision making based on iPET, and the outcome of the patients; especially if change of therapy based on iPET made any difference (as per PETAL study data).